Effects of GLP-1 Analogues on Fluid Intake in Patients With Primary Polydipsia (The GOLD-Study)
NCT02770885 on ClinicalTrials.gov · last registry update 2020-01-18
A small phase 2 — 50 participants, against a typical 110. The sponsor logged completion for 17 May 2019. Primary outcome, as filed: Fluid intake in ml.
- Status
- COMPLETED
- Phase
- P2
- Drug
- dulaglutideTrulicity
- Sponsor
- University Hospital, Basel, Switzerland
- Sponsor type
- Other
- Enrollment
- 50
- Started
- 2016-03
- Primary completion
- 2019-05-17 actual
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Fluid intake in ml
Conditions studied
Primary Polydipsia
Every field above is taken directly from the registry record. See all detected changes across the class, or the dulaglutide page for this molecule’s full trial and approval history.